Pilot Study to Determine the Utility of [18F] 3'-Deoxy-3'-Fluorothymidine- Positron Emission Tomography in Monitoring Patient Response to Chemotherapy in Neuroblastoma

Inclusion Criteria:

- All patients with neuroblastoma or suspected neuroblastoma seen at Children's
Hospital of Michigan (CHM). Patients need to be 2 years or older to be eligible for
the initial study

- Patients must be 1 day to 21 years old, there is no gender limit.

- Diagnosis: All patients with neuroblastoma or suspected neuroblastoma, including
newly diagnosed and relapsed patients, are eligible for Objective 1. To be eligible
for Objective 2, patients must have a diagnosis of neuroblastoma verified by
histology or demonstration of clumps of tumor cells in bone marrow with elevated
urinary catecholamine metabolites, and have measurable disease after the initial
surgery

- Female adolescent patients must have a negative pregnancy test within 14 days of
first imaging and should not be pregnant

- Patients must be able to lie still for the tests, or have no contraindication for
sedation

- Patients or their legal guardian must sign an informed consent indicating that they
are aware of the investigational nature of this study

- A total number of 40-50 patients will be included in the study

Exclusion Criteria:

- Patients who do not have a histology diagnosis of neuroblastoma are not eligible for
the study

- Patients whose definite diagnosis after surgery is not consistent with the diagnosis
of neuroblastoma will be included in the Objective 1 but excluded for Objective 2.